Touchstone's portfolio company, Abingdon Health Ltd (“Abingdon”), has completed a funding round raising £1.1m from current shareholders. The investment will be applied to working capital for the continued extension of the company’s lateral flow device product set and associated state-of-the-art reader systems. This includes Seralite®, its rapid test for the diagnosis and management of patients with myeloma.
Abingdon CEO, Chris Yates, commented “We are delighted to secure this funding and we thank our shareholders for their continued support. At Abingdon, we have created a growing immunodiagnostics-based rapid-test company and this additional investment will allow us to continue to develop and sell our portfolio of products and services”.